Kairamin Tablets (Busiramin)

Adult dosage

Use when adequate efficacy has not been achieved with anti-inflammatory analgesics or similar drugs. ○ Adults: The usual dose is 100 mg of bucillamine per dose, taken orally 3 times daily after meals. After an effect is achieved, the dose may be adjusted as appropriate within the range of 100～300 mg daily, according to the patient's symptoms, sensitivity, and response to this drug. The maximum daily dose is 300 mg of bucillamine.

This medication should not be used in patients with blood disorders or impaired bone marrow function. In patients with poor kidney function, serious kidney problems such as nephrotic syndrome may occur, so administration should be avoided. It is not advisable to use this medication in children as safety has not been established. Patients who have experienced allergic reactions to this medication or its components should not be administered this medication. Patients post-surgery, elderly patients, and patients in poor general condition should use this medication with caution only in special cases. Patients with a history of blood disorders, kidney disorders, or liver disorders should also use caution when administering this medication. While using this medication, serious allergic reactions such as shock or anaphylaxis may occur; therefore, if symptoms such as skin rash, vomiting, difficulty breathing, or blood pressure drop appear, administration should be stopped immediately, and treatment should be sought. If hypersensitivity reactions occur, such as skin rash, itching, urticaria, fever, or stomatitis, the administration should be reduced or discontinued. Occasionally, neurological symptoms such as drowsiness, headache, and dizziness may occur, and it is advisable to discontinue administration if these symptoms are severe. Altered taste or blurred vision, tingling in the fingers, etc., may occur, so caution is required. Gastrointestinal symptoms such as constipation, loss of appetite, nausea, vomiting, diarrhea, upper abdominal pain, and dry mouth may occur, and administration should be stopped if symptoms are severe. Respiratory side effects such as pneumonia, pleuritis, interstitial pneumonia, and pulmonary fibrosis may rarely occur, and if symptoms such as difficulty breathing, cough, or fever develop, immediate consultation with a physician is necessary. Hematological abnormalities such as aplastic anemia and leukopenia have been reported, necessitating regular blood tests before and during administration. If the white blood cell count, platelet count, or protein in urine drops below certain thresholds, administration should be discontinued. Muscle and bone disorders may occur, so if symptoms of muscle weakness or myositis appear, administration should be stopped immediately. Severe skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis may rarely occur; therefore, immediate treatment should be sought if skin abnormalities develop. Liver function abnormalities may occur, thus regular liver function tests should be conducted, and if there are issues, administration should be stopped. Kidney function may also be affected, so monthly renal function tests, including urine tests, should be performed, and if abnormalities are found, administration should be discontinued immediately. This medication is used for the treatment of chronic rheumatoid arthritis and must be administered while carefully monitoring the patient's condition and the occurrence of adverse reactions. Before administration, patients should be adequately informed of the side effects and precautions of the medication, and they should be advised to contact a physician immediately if symptoms such as throat pain, fever, bleeding tendency, or difficulty breathing occur. It is advisable to continue taking previously used anti-inflammatory analgesics until the effects are observed, and if there is no effect after 6 months of administration, it should be discontinued. Blood, kidney, and liver function tests must be conducted before and during administration, and if any abnormalities are found, administration must be stopped immediately. This medication may increase adverse reactions or decrease efficacy when used in combination with gold injections, so it is advisable not to use them together. During pregnancy, especially in late pregnancy, this medication should be avoided as it may carry the risk of premature closure of the ductus arteriosus in the fetus, and during breastfeeding, it may pass into breast milk causing side effects in infants, so breastfeeding should be stopped or drug administration halted. Safety in children has not been established, so its use is not recommended. This medication may cause false-positive reactions in ketone body tests, so care should be taken when interpreting test results. Finally, keep this medication out of the reach of children and do not transfer it to other containers.

• Shock
• symptoms resembling anaphylaxis
• erythema
• skin rash
• vomiting
• shortness of breath
• decreased blood pressure
• itching
• hives
• fever

This medication should be stored in a tightly sealed container to prevent air or moisture from entering, and it should be kept at room temperature between 1 to 30 degrees Celsius. Proper storage will maintain its efficacy and prevent deterioration.

Appearance

White round sugar-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle